Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Overall survival · treatment of relapsed epithelial ovarian cancer

Anti‐EGFR antibody plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 0.93 [0.74, 1.18]
4 studies · 658 participants
Moderate

Anti‐EGFR therapy vs placebo or usual care

Overall survival ‐ first‐line studies · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in overall survival ‐ first‐line studies compared with placebo or standard of care (moderate certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
HR 0.89 [0.76, 1.04]
3 studies · 1000 participants
Moderate

Anti‐EGFR therapy vs placebo or usual care

Overall survival ‐ recurrent disease studies · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in overall survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
HR 0.79 [0.51, 1.21]
4 studies · 489 participants
Low